Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | PLA2G2A | P14555 | 7/20 | 0.37 |
| ▸ | DHODH | Q02127 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | NPY1R | P25929 | 1/20 | 0.36 |
| ▸ | NPY2R | P49146 | 1/20 | 0.36 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.36 |
| ▸ | METAP2 | P50579 | 1/20 | 0.36 |
| ▸ | PKM | P14618 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5231036 | 0.89 | L3MBTL1 (0.43) | L3MBTL1GAAMAPTPLA2G2AALDH1A1 | |
| SCHEMBL5238926 | 0.89 | KDM4E (0.41) | L3MBTL1GAAMAPTALDH1A1LMNA | |
| SCHEMBL5233243 | 0.87 | PLA2G2A (0.38) | GAAPLA2G2AALDH1A1 | |
| SCHEMBL5234027 | 0.86 | PGR (0.43) | MAPTPLA2G2AALDH1A1 | |
| SCHEMBL5233619 | 0.86 | PLA2G2D (0.41) | ALDH1A1 | |
| SCHEMBL5233462 | 0.86 | PLA2G2D (0.41) | ALDH1A1 | |
| SCHEMBL5237418 | 0.86 | CNR2 (0.40) | PLA2G2AALDH1A1 | |
| SCHEMBL5233258 | 0.85 | MEN1 (0.38) | L3MBTL1GAAPLA2G2AALDH1A1 | |
| SCHEMBL6109513 | 0.85 | RORA (0.40) | L3MBTL1GAAPLA2G2AALDH1A1 | |
| SCHEMBL5237316 | 0.84 | PTGER4 (0.37) | GAAMAPTPLA2G2AALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1355886-B1 | FUSED HETEROCYCLIC COMPOUNDS | TAKEDA PHARMACEUTICAL (JP) | 2007-07-11 | — | — | EP | disclosed |
| US-7034039-B2 | Fused heterocyclic compounds | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2006-04-25 | — | — | US | disclosed |
| US-20040082607-A1 | Fused heterocyclic compounds | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2004-04-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040082607-A1 | Fused heterocyclic compounds | DPP7, DPP4, METAP1 | L3MBTL1 1135/4885GAA 310/4885MAPT 4855/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.